New horizons in hepatitis C antiviral therapy with direct-acting antivirals

Hepatology

Volumn 58, Issue 1, 2013, Pages 428-438

  Aghemo, Alessio ^a   De Francesco, Raffaele ^b  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b Istituto Nazionale di Genetica Molecolare   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 333; ABT 450; ACH 1625; ALS 2000; ANTIVIRUS AGENT; ASUNAPREVIR; BI 207127; BMS 791325; DACLATASVIR; DANOPREVIR; FALDAPREVIR; FILIBUVIR; GS 9256; GS 938; LEDIPASVIR; LOMIBUVIR; MERICITABINE; NECEPREVIR; NONSTRUCTURAL PROTEIN 3 SERINE PROTEASE INHIBITOR; NONSTRUCTURAL PROTEIN 4A SERINE PROTEASE INHIBITOR; NONSTRUCTURAL PROTEIN 5A INHIBITOR; NONSTRUCTURAL PROTEIN 5B POLYMERASE INHIBITOR; PEGINTERFERON; RIBAVIRIN; RITONAVIR; SERINE PROTEINASE INHIBITOR; SETROBUVIR; SIMEPREVIR; SOFOSBUVIR; SOVAPREVIR; TEGOBUVIR; TMC 43; TMC 647055; UNCLASSIFIED DRUG; UNINDEXED DRUG; VEDROPREVIR; VIRUS RNA; VX 135;

ALLOSTERISM; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; CRYSTAL STRUCTURE; DRUG BINDING; DRUG BINDING SITE; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; GENOTYPE; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LOW DRUG DOSE; METABOLIC ACTIVATION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REPLICON; REVIEW; RNA BINDING; RNA REPLICATION; SINGLE DRUG DOSE; VIRAL CLEARANCE; VIRUS ENTRY; VIRUS RESISTANCE;

ALLOSTERIC SITE; ANTIVIRAL AGENTS; CARRIER PROTEINS; HEPACIVIRUS; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; POLYETHYLENE GLYCOLS; RNA REPLICASE; SERINE PROTEINASE INHIBITORS; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84879606466     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26371     Document Type: Review

References (77)

1. Poenisch M, Bartenschlager R. New insights into structure and replication of the hepatitis C virus and clinical implications. Semin Liver Dis 2010; 30: 333-347.
2. Chang MH, Gordon LA, Fung HB. Boceprevir: a protease inhibitor for the treatment of hepatitis C. Clin Ther 2012; 34: 2021-2038.
3. Forestier N, Zeuzem S. Telaprevir for the treatment of hepatitis C. Expert Opin Pharmacother 2012; 13: 593-606.
4. Vermehren J, Sarrazin C. The role of resistance in HCV treatment. Best Pract Res Clin Gastroenterol 2012; 26: 487-503.
5. White PW, Llinas-Brunet M, Amad M, Bethell RC, Bolger G, Cordingley MG, et al. Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease. Antimicrob Agents Chemother 2010; 54: 4611-4618.
6. McPhee F, Sheaffer AK, Friborg J, Hernandez D, Falk P, Zhai G, et al. Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032). Antimicrob Agents Chemother 2012; 56: 5387-5396.
7. Agarwal A, Zhang B, Olek E, Robison H, Robarge L, et al. Rapid and sharp decline in hepatitis C virus upon monotherapy with NS3 protease inhibitor, ACH-1625. Antivir Ther 2012; 17: 1533-1539.
8. Sheng XC, Appleby T, Butler T, Cai R, Chen X, Cho A, et al. Discovery of GS-9451: an acid inhibitor of the hepatitis C virus NS3/4A protease. Bioorg Med Chem Lett 2012; 22: 2629-2634.
9. Lin TI, Lenz O, Fanning G, Verbinnen T, Delouvroy F, Scholliers A, et al. In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor. Antimicrob Agents Chemother 2009; 53: 1377-1385.
10. Seiwert SD, Andrews SW, Jiang Y, Serebryany V, Tan H, Kossen K, et al. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227). Antimicrob Agents Chemother 2008; 52: 4432-4441.
11. Wagaw S, Ravn M, Engstrom K, Xu G, Wang C, Sun Y, et al. Process for making macrocyclic oximyl hepatitis C protease inhibitors. Publication no. WO/2009/073780.
12. Sheng XC, Casarez A, Cai R, Clarke MO, Chen X, Cho A, et al. Discovery of GS-9256: a novel phosphinic acid derived inhibitor of the hepatitis C virus NS3/4A protease with potent clinical activity. Bioorg Med Chem Lett 2012; 22: 1394-1396.
13. Liverton NJ, Carroll SS, Dimuzio J, Fandozzi C, Graham DJ, Hazuda D, et al. MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease. Antimicrob Agents Chemother 2010; 54: 305-311.
14. Sarrazin C, Hezode C, Zeuzem S, Pawlotsky JM. Antiviral strategies in hepatitis C virus infection. J Hepatol 2012; 56(Suppl 1): S88-S100.
15. Summa V, Ludmerer SW, McCauley JA, Fandozzi C, Burlein C, Claudio G, et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother 2012; 56: 4161-4167.
16. Romano KP, Ali A, Aydin C, Soumana D, Ozen A, Deveau LM, et al. The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors. PloS Pathog 2012; 8: e1002832.
17. Brainard DM, Petry A, Van Dyck K, Nachbar RB, De Lepeleire I, Caro L, et al. Safety and antiviral activity of MK-5172, a novel HCV NS3/4A protease inhibitor with potent activity against known resistance mutants in genotype 1 and 3 HCV-infected patients. Hepatology 2010; 52(Suppl S1): 706A-707A.
18. Huang M, Podos S, Patel D, Yang G, Fabrycki JL, Zhao Y, et al. ACH-2684: HCV NS3 protease inhibitor with potent activity against multiple genotypes and known resistant variants. Hepatology 2010; 52(Suppl S1): 1204A.
19. Saalau-Bethell SM, Woodhead AJ, Chessari G, Carr MG, Coyle J, Graham B, et al. Discovery of an allosteric mechanism for the regulation of HCV NS3 protein function. Nat Chem Biol 2012; 8: 920-925.
20. Tellinghuisen TL, Marcotrigiano J, Rice CM. Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. Nature 2005; 435: 374-379.
21. Lemm JA, O'Boyle D 2nd, Liu M, Nower PT, Colonno R, Deshpande MS, et al. Identification of hepatitis C virus NS5A inhibitors. J Virol 2010; 84: 482-491.
22. Conte I, Giuliano C, Ercolani C, Narjes F, Koch U, Rowley M, et al. Synthesis and SAR of piperazinyl-N-phenylbenzamides as inhibitors of hepatitis C virus RNA replication in cell culture. Bioorg Med Chem Lett 2009; 19: 1779-1783.
23. Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, Fridell RA, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010; 465: 96-100.
24. Fridell RA, Wang C, Sun JH, O'Boyle DR 2nd, Nower P, Valera L, et al. Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology 2011; 54: 1924-1935.
25. Belda O, Targett-Adams P. Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein. Virus Res 2012; 170: 1-14
26. Ludmerer SW, Graham DJ, Boots E, Murray EM, Simcoe A, Markel EJ, et al. Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay. Antimicrob Agents Chemother 2005; 49: 2059-2069.
27. McCown MF, Rajyaguru S, Le Pogam S, Ali S, Jiang WR, Kang H, et al. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob Agents Chemother 2008; 52: 1604-1612.
28. Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010; 138: 447-462.
29. Lam AM, Espiritu C, Bansal S, Micolochick Steuer HM, Niu C, Zennou V, et al. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother 2012; 56: 3359-3368.
30. Svarovskaia E, Dvory-Sobol H, Gontcharova V, Chiu S, Hebner C, Hyland RH, et al. Comprehensive resistance testing in patients who relapsed after treatment with sofosbuvir (GS-7977)- containing regimens in phase 2 studies. Hepatology 2012; 56(Suppl 1): A551.
31. Beaulieu PL. The discovery of finger loop inhibitors of the hepatitis C virus NS5B polymerase: status and prospects for novel HCV therapeutics. IDrugs 2006; 9: 39-43.
32. Di Marco S, Volpari C, Tomei L, Altamura S, Harper S, Narjes F, et al. Interdomain communication in hepatitis C virus polymerase abolished by small molecule inhibitors bound to a novel allosteric site. J Biol Chem 2005; 280: 29765-29770.
33. Tomei L, Altamura S, Bartholomew L, Biroccio A, Ceccacci A, Pacini L, et al. Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. J Virol 2003; 77: 13225-13231.
34. Delang L, Froeyen M, Herdewijn P, Neyts J. Identification of a novel resistance mutation for benzimidazole inhibitors of the HCV RNA-dependent RNA polymerase. Antiviral Res 2012; 93: 30-38.
35. Larrey D, Lohse AW, de Ledinghen V, Trepo C, Gerlach T, Zarski JP, et al. Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin. J Hepatol 2012; 57: 39-46.
36. Le Pogam S, Kang H, Harris SF, Leveque V, Giannetti AM, Ali S, et al. Selection and characterization of replicon variants dually resistant to thumb- and palm-binding nonnucleoside polymerase inhibitors of the hepatitis C virus. J Virol 2006; 80: 6146-6154.
37. Poordad F, Lawitz E, Kowdley KV, Everson GT, Freilich B, Cohen D, et al. 12-Week interferon-free regimen of Abt-450/R +Abt-333+ribavirin achieved Svr12 in more than 90% of treatment-naive HCV genotype-1-infected subjects and 47% of previous non-responders. J Hepatol 2012; 56(Suppl 2): S549-S550.
38. Slater MJ, Amphlett EM, Andrews DM, Bravi G, Burton G, Cheasty AG, et al. Optimization of novel acyl pyrrolidine inhibitors of hepatitis C virus RNA-dependent RNA polymerase leading to a development candidate. J Med Chem 2007; 50: 897-900.
39. Gray F, Amphlett E, Bright H, Chambers L, Cheasty A, Fenwick R, et al. GSK625433; a novel and highly potent inhibitor of the HCVNS5B polymerase. J Hepatol 2007; 46: S225.
40. Howe AY, Cheng H, Johann S, Mullen S, Chunduru SK, Young DC, et al. Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796. Antimicrob Agents Chemother 2008; 52: 3327-3338.
41. Kneteman NM, Howe AYM, Gao TJ, Lewis J, Pevear D, Lund G, et al. HCV796: a selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus. Hepatology 2009; 49: 745-752.
42. Hebner CM, Han B, Brendza KM, Nash M, Sulfab M, Tian Y, et al. The HCV non-nucleoside inhibitor tegobuvir utilizes a novel mechanism of action to inhibit NS5B polymerase function. PLoS One 2012; 7: e39163.
43. Rai R, Deval J. New opportunities in anti-hepatitis C virus drug discovery: targeting NS4B. Antiviral Res 2011; 90: 93-101.
44. Einav S, Gerber D, Bryson PD, Sklan EH, Elazar M, Maerkl SJ, et al. Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysis. Nat Biotechnol 2008; 26: 1019-1027.
45. Choong IC, Cory D, Glenn JS, Yang W. Methods and compositions of treating a Flaviviridae family viral infection. Publication no. WO/2010/107739.
46. Esser-Nobis K, Romero-Brey I, Ganten TM, Gouttenoire J, Harak C, Klein R, et al. Analysis of hepatitis C virus resistance to silibinin in vitro and in vivo points to a novel mechanism involving nonstructural protein 4B. Hepatology 2013; 57: 953-963.
47. Steinmann E, Whitfield T, Kallis S, Dwek RA, Zitzmann N, Pietschmann T, et al. Antiviral effects of amantadine and iminosugar derivatives against hepatitis C virus. Hepatology 2007; 46: 330-338.
48. Vausselin T, Calland N, Belouzard S, Descamps V, Douam F, Helle F, et al. The antimalarial ferroquine is an inhibitor of hepatitis C virus. Hepatology 2013; 58: 86-97.
49. Aghemo A, Degasperi E, Colombo M. Directly acting antivirals for the treatment of chronic hepatitis C: unresolved topics from registration trials. Dig Liver Dis 2012; doi: 10.1016/j.dld.2012.05.002.
50. Ciesek S, von Hahn T, Manns MP. Second-wave protease inhibitors: choosing an heir. Clin Liver Dis 2011; 15: 597-609.
51. Lewis H, Cunningham M, Foster G. Second generation direct antivirals and the way to interferon-free regimens in chronic HCV. Best Pract Res Clin Gastroenterol 2012; 26: 471-485.
52. Poordad F, Dieterich D. Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents. J Viral Hepat 2012; 19: 449-464.
53. Wartelle-Bladou C, Le Folgoc G, Bourliere M, Lecomte L. Hepatitis C therapy in non-genotype 1 patients: the near future. J Viral Hepat 2012; 19: 525-536.
54. Hezode C, Shiffman ML, Cooper C, Everson GT, Marcellin P, Rodriguez-Torres M, et al. Ritonavir-boosted danoprevir plus Peg-IFNβ-2a/ribavirin (P/R) demonstrates up to 100% SVR24 with 12 or 24 weeks of total treatment in treatment-naive patients with HCV genotype 4 infection in the DAUPHINE study. Hepatology 2012; 56(Suppl S1): 557A.
55. Hezode C, Shiffman ML, Cooper C, Everson GT, Marcellin P, Rodriguez-Torres M, et al. Daclatasvir, an NS5A replication complex inhibitor, combined with peginterferon Alfa-2a and ribavirin in treatment-naive HCV-genotype 1 or 4 subjects: phase 2b COMMAND-1 SVR12 results. Hepatology 2012; 56(Suppl S1): 553A.
56. Gish RG, Meanwell NA. The NS5A replication complex inhibitors: difference makers? Clin Liver Dis 2011; 15: 627-639.
57. Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012; 366: 216-224.
58. Hassanein T, Lawitz E, Crespo I, Davis M, DeMicco MP, Nelson DR, et al. Once daily sofosbuvir (GS-7977) plus PEG/RBV: high early response rates are maintained during post-treatment follow-up in treatment-naïve patients with HCV genotype 1, 4, and 6 infection in the ATOMIC Study. Hepatology 2012; 56(Suppl S1): 307A.
59. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 368: 34-44.
60. Osinusi A, Heytens L, Lee YJ, Bon D, Shivakumar B, Nelson A, et al. High efficacy of GS-7977 in combination with low or full dose ribavirin for 24 weeks in difficult to treat HCV infected genotype 1 patients: interim analysis from the SPARE Trial [Abstract]. In: 63rd Annual Meeting of the American Association for the Study of Liver Diseases; November 9-13, 2012; Boston, MA. Abstract LB-4.
61. Welzel TM, Zeuzem S. Mixing and matching drugs: what makes sense? Clin Liver Dis 2011; 15: 657-664.
62. Kowdley KV, Lawitz E, Poordad F, Cohen DE, Nelson DR, Zeuzem S, et al. A 12-week interferon-free treatment regimen with ABT-450/r, ABT-267, ABT-333 and ribavirin achieves SVR12 rates (observed data) of 99% in treatment-naïve patients and 93% in prior null responders with HCV genotype1 infection [Abstract]. In: 63rd Annual Meeting of the American Association for the Study of Liver Diseases; November 9-13, 2012; Boston, MA. Abstract LB-1.
63. Everson GT, Sims KD, Rodriguez-Torres M, Hezode C, Lawitz E, Bourliere M, et al. An interferon-free, ribavirin-free 12-week regimen of daclatasvir (DCV), asunaprevir (ASV), and BMS-791325 yielded SVR4 of 94% in treatment-naïve patients with genotype (GT) 1 chronic hepatitis C virus (HCV) infection [Abstract]. In: 63rd Annual Meeting of the American Association for the Study of Liver Diseases; November 9-13, 2012; Boston, MA. Abstract LB-3.
64. Sulkowski MS, David F, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, et al. High rate of sustained virologic response with the all-oral combination of daclatasvir (NS5A inhibitor) plus sofosbuvir (nucleotide NS5B inhibitor), with or without ribavirin, in treatment-naïve patients chronically infected with HCV genotype 1, 2, or 3 [Abstract]. In: 63rd Annual Meeting of the American Association for the Study of Liver Diseases; November 9-13, 2012; Boston, MA. Abstract LB-2.
65. Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepat 2008; 49: 634-651.
66. Tanwar S, Trembling PM, Dusheiko GM. TMC435 for the treatment of chronic hepatitis C. Expert Opin Investig Drugs 2012; 21: 1193-1209.
67. Eley T, He B, Li J, Colston E, Child M, Bedford BR, et al. Effect of Hepatic impairment on the pharmacokinetics of asunaprevir (BMS-650032, ASV). Hepatology 2012; 56(Suppl S1): A1065.
68. Fontana RJ, Hughes EA, Appelman H, Hindes R, Dimitrova D, Bifano M. Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation. Liver Transpl 2012; 18: 1053-1059.
69. Fontana RJ, Bifano M, Hindes R, Symonds WT, Dimitrova D. First ever successful use of daclatasvir and GS-7977, an interferon-free oral regimen, in a liver transplant recipient with severe recurrent Hepatitis C. Hepatology 2012; 56(Suppl S1): A524.
70. Suzuki Y, Ikeda K, Suzuki F, Toyota J, Karino Y, Chayama K, et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol 2012; doi 10.1016/j.jhep.2012.09.037.
71. Camma C, Petta S, Enea M, Bruno R, Bronte F, Capursi V, et al. Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. Hepatology 2012; 56: 850-860.
72. Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD. New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med 2012; 156: 279-290.
73. Dusheiko G, Wedemeyer H. New protease inhibitors and direct-acting antivirals for hepatitis C: interferon's long goodbye. Gut 2012; 61: 1647-1652.
74. Pawlotsky JM. Is hepatitis virus resistance to antiviral drugs a threat? Gastroenterology 2012; 142: 1369-1372.
75. Sun JH, O'Boyle IiDR, Zhang Y, Wang C, Nower P, Valera L, et al. Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5A replication complex inhibitor, BMS-790052. Hepatology 2012; 55: 1692-1699.
76. Galmozzi E, Aghemo A, Colombo M. Low rates of naturally occurring resistant variants to the NS5A inhibitor daclatasvir in HCV-1 null responders. Hepatology 2013; 57: 2087.
77. Karino Y, Toyota J, Ikeda K, Suzuki F, Chayama K, Kawakami Y, et al. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J Hepatol 2012; doi 10.1016/j.jhep.2012.11.012.